TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.

Murdo Ferguson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.